| h-48775971 | Gut-Brain Axis Microbiome Modulation | 0.56 | 0.40 | GPR43, GPR109A | debated | 2026-04-04 | SDA-2026-04-04-gap-20260404-microglial-priming-early-ad |
| h-da0eec2bdf | Perivascular Dimensionality: GluN2B Control of Thalamocortical vs. Corticopial G | 0.56 | 0.52 | GRIN2B activity pattern; topological glymphatic routing | proposed | 2026-04-28 | SRB-2026-04-28-h-var-e2b5a7e7db |
| h-15d40f8710 | Sticker-Spacer Phase Behavior Determines Recruitment Hierarchy | 0.56 | 0.65 | 53BP1/TP53BP1 | proposed | 2026-04-21 | SDA-2026-04-10-gap-debate-20260410-075026-23501c3c |
| hyp_test_852af3c6 | Test: TREM2 enhances amyloid clearance | 0.56 | 0.33 | TREM2 | proposed | 2026-04-17 | test-hypothesis-fixtures-v1 |
| h-var-e53ee5ba83 | Optogenetic restoration of hippocampal gamma oscillations via channelrhodopsin-2 | 0.56 | 0.71 | PVALB | promoted | 2026-04-21 | SDA-2026-04-03-26abc5e5f9f2 |
| h-var-3fbcfc0e6c | CYP46A1 Gene Therapy for Age-Related TREM2-Mediated Microglial Senescence Revers | 0.55 | 0.65 | CYP46A1 | proposed | 2026-04-07 | SDA-2026-04-26-trem2-showcase |
| h-eef1be45 | Inhibitory Neuron-Selective WNT Signaling Restoration | 0.55 | 0.30 | WNT3A, CTNNB1, TCF7L2 | proposed | 2026-04-04 | SDA-2026-04-03-gap-debate-20260403-222543-20260402 |
| h-cd49366c | Profilin-1 Cytoskeletal Checkpoint Enhancement | 0.55 | 0.40 | PFN1 | proposed | 2026-04-04 | SDA-2026-04-03-gap-aging-mouse-brain-v3-20260402 |
| h-04a4889c | Dual NF-κB/MMP Inhibition Strategy | 0.55 | 0.56 | NFKB1 | proposed | 2026-04-16 | SDA-2026-04-16-gap-bbb-tjp-20260416041707 |
| h-1dd95a85f3 | Fusing IGFBPL1 to IGF-1 for Receptor-Mediated BBB Transcytosis | 0.55 | 0.52 | IGFBPL1 | proposed | 2026-04-22 | SDA-2026-04-06-gap-debate-20260406-062045-6addd0cf |
| h-23e3985d | APOE4 Isoform Correction via Lipidation Enhancement as CTE Risk Mitigation | 0.55 | 0.85 | APOE | proposed | 2026-04-15 | SDA-2026-04-14-gap-pubmed-20260410-185318-186b0446 |
| h-1333080b | P2RX7-Mediated Exosome Secretion Blockade | 0.55 | 0.70 | P2RX7 | promoted | 2026-04-12 | SDA-2026-04-04-gap-tau-prop-20260402003221 |
| h-0b5a6761 | MFSD2A-Targeted Lysophosphatidylcholine-SPM Conjugates as CNS-Penetrant Pro-Reso | 0.55 | 0.68 | MFSD2A (SLC59A1) | promoted | 2026-04-13 | SDA-2026-04-12-gap-debate-20260410-113110-2059f65f |
| h-var-0162bdbc90 | Closed-loop transcranial focused ultrasound to restore hippocampal gamma oscilla | 0.55 | 0.71 | AQP4 | promoted | 2026-04-21 | SDA-2026-04-03-26abc5e5f9f2 |
| h-var-ce29b18697 | Temporal NLRP3 Inhibition During SPP1-Driven Microglial Activation Windows | 0.55 | 0.40 | NLRP3 | promoted | 2026-04-20 | SDA-2026-04-15-gap-pubmed-20260406-062118-e3613755 |
| h-var-e607efdac0 | Astrocytic SPP1 Modulation Through STAT3-Dependent Transcriptional Control | 0.55 | 0.40 | SPP1 | promoted | 2026-04-20 | SDA-2026-04-15-gap-pubmed-20260406-062118-e3613755 |
| h-27bc0569 | Liquid-Liquid Phase Separation Modifier Therapy | 0.55 | 0.55 | G3BP1 | proposed | 2026-04-03 | SDA-2026-04-01-gap-9137255b |
| h-var-5900d71273 | Gamma-Entrained PV Interneuron Networks Enable Precision p-tau217-Guided lncRNA | 0.55 | 0.39 | PVALB, CREB1, lncRNA-0021/lncRNA-9969 | promoted | 2026-04-20 | SDA-2026-04-16-gap-pubmed-20260410-150509-76c40dac |
| h-5a4efb713f | Astrocyte Reactivity Reprogramming via A1/A2 Phenotype Modulation | 0.55 | 0.62 | IL1A/TNF/C1Q | proposed | 2026-04-29 | SDA-2026-04-28-gap-test-20260425-224949 |
| h-analogy-ceb122df | TREM2-complement-amyloid axis as therapeutic target for protein aggregation diso | 0.55 | 0.45 | TREM2 | active | 2026-04-28 | |
| h-analogy-daabed82 | TREM2-Modulating LNPs for Neurodegeneration: Cell-Type-Specific Immunometabolic | 0.55 | 0.45 | TREM2 | active | 2026-04-28 | |
| h-0ba94d1485 | Small-Molecule FUS Nuclear Import Correctors Rescue Motor Neuron Toxicity | 0.55 | 0.70 | FUS | proposed | 2026-04-26 | test-hypothesis-fixtures-v1 |
| h-434c5d45f5 | Dual-Mechanism Model: G2019S Increases Both Baseline AND Signal-Dependent Phosph | 0.55 | 0.55 | LRRK2 | proposed | 2026-04-26 | SDA-2026-04-23-gap-debate-20260417-033119-54941818 |
| h-f5e072feff | TLR2 Recognition of Gut-Derived Fungal and Bacterial D-Alanylated Lipoteichoic A | 0.55 | 0.62 | TLR2, MyD88, NFATC1, PTGS2 (COX-2), PTGER2 (EP2), C3 | proposed | 2026-04-26 | SDA-2026-04-26-gap-20260425-225305 |
| h-86101c8cd6ec | Developmental stage-specific dominance of tau vs MAP6 function | 0.55 | 0.55 | MAPT | proposed | 2026-04-26 | paper-39257379 |
| h-b8724fde927e | Neuronal-specific domain stabilization | 0.55 | 0.55 | ANK2 | proposed | 2026-04-26 | paper-40040809 |
| h-a40b5598 | BET Bromodomain Inhibition for Neuroinflammation Suppression | 0.55 | 0.65 | BRD4 | proposed | 2026-04-26 | SDA-2026-04-16-gap-epigenetic-adpdals |
| h-80ac3d8b6e | Metabolic Rescue PDH Activation (H5): Indirect Lipogenesis Suppression | 0.55 | 0.55 | PDHA1 (Pyruvate dehydrogenase α1) | proposed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260410-180918-962b1ada-debate |
| h-94d6ba316c | EP4 Receptor Agonism for SLC7A11 Upregulation | 0.55 | 0.58 | PTGER4 (EP4 receptor) → SLC7A11 transcription | proposed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260410-174000-6451afef-debate |
| h-b53b88f02f | GPX4 Activation as Neuroprotective Strategy | 0.55 | 0.70 | GPX4 (glutathione peroxidase 4) | proposed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260410-174000-6451afef-debate |
| h-9e877c49ba | Physiological SCFAs may worsen alpha-synuclein pathology through FFAR2/GPR43-NLR | 0.55 | 0.67 | FFAR2/NLRP3/IL1B | proposed | 2026-04-25 | SDA-2026-04-25-gapdebate-18cce7b525 |
| h-d12d82fb56 | GPP Repeat Peptide-Fc Fusion for Enhanced Brain Penetration | 0.55 | 0.52 | SLC15A2 (PepT2); FCGRT (FcRn) | proposed | 2026-04-22 | SDA-2026-04-02-gap-bbb-antibody-transport |
| h-80d39d9095 | Disrupting Muscarinic M1/M3 Receptor-Mediated Tau Internalization and Synaptic T | 0.55 | 0.58 | CHRM1 (M1R) | proposed | 2026-04-22 | SDA-2026-04-04-gap-tau-prion-spreading |
| h-ad2607a5c9 | H7: NEAT1 Epigenetic Rewiring Under Proteotoxic Stress | 0.55 | 0.58 | NEAT1, METTL14, YTHDC1 (m6A reader) | proposed | 2026-04-22 | SDA-2026-04-04-gap-20260404-120802 |
| h-a3998f0e46 | Surface Exposure of SENP1-β1 Integrin Complex Enables Targeted Senolytic Elimina | 0.55 | 0.52 | SENP1, ITGB1 (β1 integrin), ITGAM (CD11b) | proposed | 2026-04-22 | SDA-2026-04-06-gap-debate-20260406-062101-6af4ba5f |
| h-5b6ec35742 | H2: SASP Neutralization via JAK/STAT Inhibition Preserves Astrocyte Function | 0.55 | 0.52 | IL6R; JAK1; STAT3 | proposed | 2026-04-22 | SDA-2026-04-06-gap-debate-20260406-062101-5d7b9dc0 |
| h-811f3e6d09 | RNA Sequence Elements as Primary Specificity Determinants | 0.55 | 0.58 | TIA1, HuR, FMRP, G3BP1 | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-041428-53b81741 |
| h-65d6aa9d6c | oxLDL/LOX-1/ROS Signaling Induces P2RY12 via Nrf2 Activation | 0.55 | 0.55 | OLR1 (LOX-1), NFE2L2 (Nrf2) | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-041434-a4d6154a |
| h-25be864e | H63D HFE Genotype-Guided Iron Chelation Therapy for Subset-Selected ALS Patients | 0.55 | 0.55 | HFE (H63D variant) | proposed | 2026-04-17 | SDA-2026-04-16-gap-ferroptosis-als-d2fb6bf796ed |
| h-43ec636e | Oligodendrocyte DNA Repair Enhancement | 0.55 | 0.30 | PARP1 | proposed | 2026-04-14 | SDA-2026-04-03-gap-seaad-v4-20260402065846 |
| h-b0cda336 | Digital Twin-Guided Metabolic Reprogramming | 0.55 | 0.50 | PPARGC1A/PRKAA1 | promoted | 2026-04-02 | sda-2026-04-01-gap-012 |
| h-9cd3aac2 | CYP46A1 Activation as a Therapeutic Strategy to Restore Neuronal Cholesterol Eff | 0.55 | 0.60 | CYP46A1 | proposed | 2026-04-26 | SDA-2026-04-16-frontier-lipidomics-dcdbc360 |
| h-49112ee4c0 | A pre-organized hairpin or loop in lncRNA-0021 creates a high-affinity docking s | 0.55 | 0.46 | lncRNA-0021 | proposed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260410-150509-76c40dac-debate |
| h-292a1ec3 | Combined NAMPT-Alectinib Targeting of SASP-Complement Cascade | 0.55 | 0.50 | NAMPT, SIRT1, C1QA/C1QB/C1QC, IL1B | proposed | 2026-04-17 | SDA-2026-04-16-gap-pubmed-20260410-095709-4e97c09e |
| h-91bdb9ad | Miro1-Mediated Mitochondrial Trafficking Enhancement Therapy | 0.55 | 0.50 | RHOT1 | proposed | 2026-04-03 | SDA-2026-04-01-gap-20260401231108 |
| h-a968e9c3b5 | Multi-Chaperone System Co-Activation Prevents Saturation Through Complementary S | 0.55 | 0.72 | DNAJB1, HSP90AA1/HSP90AB1, STIP1 (HOP) | proposed | 2026-04-22 | SDA-2026-04-06-gap-debate-20260406-062052-28cbc764 |
| h-3d2aa5a6 | YWHAG-Mediated TFEB Subcellular Targeting | 0.55 | 0.30 | YWHAG | proposed | 2026-04-04 | SDA-2026-04-03-gap-debate-20260403-222617-8eb5bdbc |
| h-6636218992 | TRIM21-Mediated Ubiquitination Creates Peripheral Epitope Gradient via K63-Linke | 0.55 | 0.58 | TRIM21 | proposed | 2026-04-21 | SDA-2026-04-08-gap-pubmed-20260406-041423-9c2c2ee3 |
| h-646ae8f1 | Perinatal Hypoxia-Primed Microglia Targeting | 0.55 | 0.30 | HIF1A, NFKB1 | debated | 2026-04-04 | SDA-2026-04-04-gap-20260404-microglial-priming-early-ad |
| h-69ce9196 | SYK-Independent TREM2 Pathways Remain Functional in TYROBP Deficiency | 0.55 | 0.50 | SYK, TREM2 | promoted | 2026-04-15 | SDA-2026-04-14-gap-pubmed-20260411-072446-a32fa49c |